Latest Chorea Stories
LA JOLLA, Calif., March 24, 2014 /PRNewswire/ -- Auspex Pharmaceuticals, Inc.
LA JOLLA, Calif., Jan.
Results achieved over 80 weeks of treatment consistent with statistically significant reduction in chorea demonstrated in pivotal study.
By Rita Rubin Baylor College of Medicine neurologist Joseph Jankovic is a patient man. With the Food and Drug Administration's OK, Jankovic has studied the drug tetrabenazine since 1979.
Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced it has acquired Prestwick Pharmaceuticals, Inc., a privately held, U.S.-based pharmaceutical company that holds the Canadian and U.S. licensing rights to Xenazine(R) (tetrabenazine tablets).
OVATION Pharmaceuticals, Inc. announced today that it has acquired from Prestwick Pharmaceuticals the exclusive license in the United States to commercialize Xenazine(R) (tetrabenazine), an orphan drug recently approved by the U.S.
The U.S. Food and Drug Administration announced approval of Xenazine (tetrabenazine) for the treatment of chorea in people with Huntington's disease.
NEW YORK, Aug. 15 /PRNewswire/ -- The Hereditary Disease Foundation (HDF) is extremely pleased the U.S. Food and Drug Administration has approved Xenazine, or tetrabenazine, for the treatment of chorea associated with Huntington's disease.
WASHINGTON, Aug. 15 /PRNewswire/ -- Prestwick Pharmaceuticals, Inc., a privately-held pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved XENAZINE(R) (tetrabenazine) for the treatment of chorea associated with Huntington's disease (HD).